Home Cannabis What Analysts Are Recommending for Trulieve Cannabis

What Analysts Are Recommending for Trulieve Cannabis

Analysts’ recommendation

Of the three analysts that follow Trulieve Cannabis (TRUL) (TCNNF), one analyst has given the stock a “strong buy” rating, while the other two analysts are favoring a “buy” rating. On average, analysts have given the stock a price target of 26 Canadian dollars, which represents an upside potential of 44.8% from its February 22 closing price of 17.96 Canadian dollars.

3

Peer comparisons

  • Of the seven analysts that cover Tilray (TLRY), three have given it “buys,” and four have given it “holds.” On average, analysts have given the stock a price target of $131.25, which represents a potential upside of 66% from its February 22 closing price of $79.07.
  • Of the 11 analysts that follow HEXO (HEXO), three analysts have given it a “strong buy” rating, and eight have given it “buy” ratings. On average, analysts have set a price target of 9.66 Canadian dollars on the stock, which represents a potential upside of 24.6% from its February 22 closing price of 7.75 Canadian dollars.
  • Of the ten analysts that follow Aphria (APHA), seven analysts are favoring a “buy,” while two analysts have given it a “hold” rating and one analyst has given it a “sell” rating. On average, analysts have given APHA a price target of 16.25 Canadian dollars, which represents a potential upside of 22.1% from its February 22 closing price of 13.31 Canadian dollars.

Valuation multiples

As of February 22, Trulieve was trading at a forward EV-to-sales multiple of 0.57x. On the same day, its peers Tilray, HEXO, and Aphria were trading at a forward EV-to-sales multiple 37.3x, 7.93x, and 4.88x, respectively.

Also, on the same day, Trulieve was trading at a forward EV-to-EBITDA multiple of 1.28x. Peers HEXO and Aphria were trading at a forward EV-to-EBITDA multiple of 36.8x and 40.8x, respectively.

Must Read